Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lineage Cell Therapeutics, Inc. LCTX

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, a oligodendrocyte progenitor cell therapy for...


Recent & Breaking News (NYSEAM:LCTX)

Asterias Biotherapeutics Completes Public Offering and Private Placement of Common Stock

PR Newswire February 10, 2015

OncoCyte to Present Cancer Diagnostic Clinical Study Data at AACR Annual Meeting

Business Wire February 6, 2015

Asterias Biotherapeutics Prices Public Offering of Common Stock

PR Newswire February 5, 2015

Asterias Biotherapeutics Announces Public Offering of Common Stock

PR Newswire February 4, 2015

BioTime Announces Issuance of 14 New Patents in the Fields of Regenerative Medicine, Stem Cell Technology, and Cancer Therapy

Business Wire January 26, 2015

BioTime Subsidiary OncoCyte Corporation Appoints William Annett to Its Board of Directors

Business Wire January 12, 2015

BioTime Appoints Adi Mohanty Chief Operating Officer

Business Wire December 29, 2014

BioTime Subsidiary ES Cell International and GE Healthcare Cross-License patents in the Field of Cell Assays for Drug Testing

Business Wire December 15, 2014

BioTime, Inc. Subsidiary OncoCyte Corporation Completes Initial Enrollment of Clinical Study of Urine-Based Bladder Cancer Diagnostic

Business Wire December 15, 2014

BioTime Appoints Angus C. Russell to Board of Directors

Business Wire December 15, 2014

BioTime to Host Investor and Analyst Day on December 15, 2014

Business Wire December 12, 2014

Asterias Biotherapeutics Reports Third Quarter Financial and Operating Results

PR Newswire November 10, 2014

BioTime Reports Third Quarter Results and Recent Progress

Business Wire November 10, 2014

BioTime Receives Authorization to Begin Pivotal Human Clinical Trial of Renevia(TM) in Europe

Business Wire November 4, 2014

BioTime's Subsidiary Cell Cure Neurosciences Receives FDA Authorization to Initiate Phase I/IIa Trial of Embryonic Stem Cell-Derived OpRegen® for the Treatment of the Dry Form of Age-Related Macular Degeneration

Business Wire November 3, 2014

Asterias Biotherapeutics to Report Third Quarter Results on November 10, 2014

PR Newswire October 31, 2014

Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury

PR Newswire October 20, 2014

BioTime, Inc. Closes $31 Million Financing

Business Wire October 9, 2014

Asterias Biotherapeutics to List its Series A Common Stock on NYSE MKT

PR Newswire October 6, 2014

Michael H. Mulroy and Stephen L. Cartt Joining BioTime Board of Directors

Business Wire October 6, 2014